Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

Mandrekar SJ, Sargent DJ.

J Clin Oncol. 2009 Aug 20;27(24):4027-34. doi: 10.1200/JCO.2009.22.3701. Epub 2009 Jul 13.

2.

Clinical trial designs for predictive biomarker validation: one size does not fit all.

Mandrekar SJ, Sargent DJ.

J Biopharm Stat. 2009;19(3):530-42. doi: 10.1080/10543400902802458.

3.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

4.

Genomic and molecular profiling predicts response to temozolomide in melanoma.

Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS.

Clin Cancer Res. 2009 Jan 15;15(2):502-10. doi: 10.1158/1078-0432.CCR-08-1916. Erratum in: Clin Cancer Res. 2009 May 1;15(9):3240.

5.

A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7. doi: 10.1073/pnas.0806674105. Epub 2008 Dec 2. Erratum in: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6878. Retraction in: Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569.

6.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

7.

A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG.

Mol Cancer Ther. 2008 Oct;7(10):3141-9. doi: 10.1158/1535-7163.MCT-08-0642. Erratum in: Mol Cancer Ther. 2012 May;11(5):1214-5.

8.

Toward the individualization of lung cancer therapy.

Anguiano A, Nevins JR, Potti A.

Cancer. 2008 Oct 1;113(7 Suppl):1760-7. doi: 10.1002/cncr.23644.

9.

Randomized phase III clinical trial designs for targeted agents.

Hoering A, Leblanc M, Crowley JJ.

Clin Cancer Res. 2008 Jul 15;14(14):4358-67. doi: 10.1158/1078-0432.CCR-08-0288.

10.

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ.

Clin Trials. 2008;5(3):181-93. doi: 10.1177/1740774508091815.

11.

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A.

PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908. Retraction in: PLoS One. 2011;6(9). doi: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4.

12.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

13.

Clinical application of the 70-gene profile: the MINDACT trial.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.

J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

PMID:
18258980
14.

Development of the 21-gene assay and its application in clinical practice and clinical trials.

Sparano JA, Paik S.

J Clin Oncol. 2008 Feb 10;26(5):721-8. doi: 10.1200/JCO.2007.15.1068. Review.

PMID:
18258979
15.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
16.

Genomic strategies for personalized cancer therapy.

Garman KS, Nevins JR, Potti A.

Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32. Review.

PMID:
17911165
17.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

18.

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.

Wang SJ, O'Neill RT, Hung HM.

Pharm Stat. 2007 Jul-Sep;6(3):227-44.

PMID:
17688238
19.

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.

Bonomi PD, Buckingham L, Coon J.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. Review.

20.

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

Jiang W, Freidlin B, Simon R.

J Natl Cancer Inst. 2007 Jul 4;99(13):1036-43. Epub 2007 Jun 27.

PMID:
17596577

Supplemental Content

Support Center